Head-to-head · Cost-Efficiency Index
AZ Health vs Blue Haven RX
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
AZ Health
Cost-first shoppers who want transparent flat-rate compounded GLP-1 pricing in the roughly half of states it covers, if you confirm eligibility first.
Visit AZ HealthBlue Haven RX
Shoppers who read the FAQ carefully before trusting the homepage price.
Visit Blue Haven RXThe verdict
AZ Health and Blue Haven RX tie on the Cost-Efficiency Index at 61/100, so neither wins outright on the numbers. For most shoppers we'd start with AZ Health (ranked #223, a hair above #225) — Cost-first shoppers who want transparent flat-rate compounded GLP-1 pricing in the roughly half of states it covers, if you confirm eligibility first. But Blue Haven RX is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs AZ Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | AZ Health | Blue Haven RX |
|---|---|---|
| Cost-Efficiency Index | 61/100 | 61/100 |
| Semaglutide / mo | $179/mo (starting dose, compounded) | $149/mo (all doses, compounded) |
| Tirzepatide / mo | $199/mo (starting dose, compounded) | $179/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $2,148 | $1,788 |
| Tirzepatide / yr (modeled) | $2,388 | $2,148 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #223 | #225 |
AZ Health
61/100Where the value is
- Transparent flat monthly pricing published up front — semaglutide from $179/mo, tirzepatide from $199/mo, no insurance required
- Discloses plainly that compounded medications are not FDA-approved
- FSA/HSA eligible, free discreet shipping, and cancel-anytime language
The tradeoffs
- Coverage is stated only as '50% States Covered' with no state list published — you cannot confirm eligibility before starting
- The.org domain and thin site (an /faq link 404s) are unusual for a commercial telehealth business and warrant extra caution
Blue Haven RX
61/100Where the value is
- Claims flat, dose-independent pricing ('no price increases' regardless of dose)
- Routes to established physician networks (Wasef Health, Beluga Health) rather than an unknown in-house provider
- Payments held until doctor approval, per site copy, reducing risk of paying for a declined prescription
The tradeoffs
- Internal pricing contradiction: homepage says tirzepatide is $179/month, FAQ says $259/month
- No named medical director
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.